Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs

Summary

GBI Research, the leading business intelligence provider, has released its latest research Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs. The report provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in the US with key data, information and analysis of pricing and reimbursement decisions across the US. The report closely scrutinizes major changes in pharmaceuticals-related pricing and reimbursement in the US in the recent past and the impact these changes will have in the future. It also describes the efforts taken by the US government and private sector in shaping the pricing and reimbursement policies of brand name and generic drugs. The pricing and reimbursement scenario in some of the major therapy areas of the US has been described with the help of informative case studies.

GBI Research has found that expenditures towards healthcare have increased in the US which has led to an increased life expectancy among the Americans. When compared to the top five countries of Europe (France, Germany, the UK, Italy and Spain), the US has the highest per capita expenditures on healthcare. Out-of-pocket spending is minimal in the US, due to a strong reimbursement system provided by the public and private sector, that covers most age groups and communities. A majority of the US population is under insurance coverage, with private health insurance having a larger share than government health insurance. Most of the states have developed their own insurance plans for the benefit of their residents.

With an increase in the working class and ageing population, chronic diseases, age-related diseases and diseases due to sedentary lifestyle are expected to rise in the future indicating increasing healthcare expenditures. The US President has been implementing a number of changes in the reimbursement system in order to reduce national deficits. The Patient Protection and Affordable Care Act (PPACA) has been introduced to take care of the deficits. The US budget has been designed to reduce deficits and bring about major reforms in the healthcare system of the US.

Scope

- Detailed study of the healthcare systems in the US.
- Political, economical, social and technological analysis of the US pharmaceutical industry.
- Analysis of the pricing and reimbursement mechanisms in the US.
- Key trends that follow from the recent changes brought about in the pricing and reimbursement system.
- Build an understanding of the possible major challenges that may arise due to the changes in the pricing and reimbursement scene in the US.
- Insight into various reimbursement programs in the US with case studies.
- Particular focus on the pricing and reimbursement in major therapy areas with case studies.

Reasons to buy

- Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in the US.
- Optimize your investment through identification and understanding of the changes in the pharmaceuticals regulatory mechanism in the US.
- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene of the US.
- Improve negotiations with the government agencies to maximize reimbursement of drugs by understanding the mechanisms involved.